This technology utilizes a DNA-templated micelle platform to selectively target the delivery of therapeutic drugs and genes to a wide range of cells.
Currently used nanoparticles can be formed into nanocarriers or conjugated to ligands for the delivery of chemotherapeutic agents. However, as nanomedicine becomes an emerging field in cancer treatment, the development of safe and consistent delivery platforms has become a prominent challenge. The use of nanocarriers poses a threat of nanotoxicity, in addition to inconsistent batch effects. Furthermore, concerns over loss of drug efficacy during encapsulation and delivery limit the scalability of the technology. As a result, there is continued demand for methods to effectively co-deliver multiple therapeutic cargo.
This platform implements DNA templates ligated to amine-functionalized polyethylene glycol (PEG) segments in order to form nanoparticle-sized micelles capable of efficiently delivering small nucleic acids and therapeutic drugs to target cells. The DNA bridge serves as modifiable template that can load a siRNA, gRNA, mRNA, or chemodrugs of interest, while the micelles can be conjugated with a customizable targeting peptide. The use of the DNA template allows not only heterogeneity within the micelle to carry multiple delivery agents, but also permits enhanced control over micelle formation, reducing the polydispersity and inconsistent batch effects.
This technology has been validated in vitro in cell lines and tumors.
Patent Pending
IR CU17119
Licensing Contact: Joan Martinez